NFKB1 and cardiac hypertrophy: In vitro studies suggested a novel mechanism that AS-1 attenuates hypertension-induced cardiac hypertrophy is mediated by downregulation of miRNA-143 in a NF-κB-dependent manner, which could be a new therapeutic target in the treatments of hypertension-induced cardiac hypertrophy.